

# HJR162 ENROLLED



1 HJR162  
2 3P1PJZE-2  
3 By Representatives Oliver, Reynolds  
4 RFD: Rules  
5 First Read: 24-Feb-26



## HJR162 Enrolled

1 Enrolled, An Act,

2

3

4 ENCOURAGING THE ALABAMA MEDICAID AGENCY TO EVALUATE THE  
5 OVERALL COSTS OF GLP-1 MEDICATIONS AND REPORT ITS FINDINGS.

6

7 WHEREAS, obesity is caused by a complex mix of  
8 environmental and biological factors, and it puts  
9 individuals at risk for other diseases, such as heart  
10 disease and diabetes; and

11 WHEREAS, in 2019, the Centers for Disease Control  
12 reported that obesity accounted for nearly \$173 billion in  
13 medical expenditures annually in the United States;  
14 GlobalData estimates that obesity has negatively impacted  
15 the State of Alabama's GDP by \$7.2 billion and annually  
16 impacts the state budget by over \$750 million; 2024  
17 Behavioral Risk Factor Surveillance System data estimates  
18 the prevalence of obesity in Alabama is estimated at 38.9  
19 percent for adults and 15.6 percent for children enrolled in  
20 the Women, Infants, and Children program in Alabama; and

21 WHEREAS, the Centers for Medicare and Medicaid  
22 Services recently launched two new drug pricing models that  
23 could positively impact Medicaid programs; the true impact  
24 will be known when the participating manufacturers and  
25 medications are announced by Spring 2026, approximately; and

26 WHEREAS, the Alabama Medicaid Agency estimates  
27 approximately 110,000 adult and child members may qualify  
28 for GLP-1 medications for weight management based on current



## HJR162 Enrolled

29 FDA labeling; it is important to determine whether GLP-1  
30 medications could benefit Alabamians; now therefore,

31 BE IT RESOLVED BY THE LEGISLATURE OF ALABAMA, BOTH  
32 HOUSES THEREOF CONCURRING, That the Alabama Medicaid Agency  
33 is encouraged to:

34 (1) Determine actual savings that might exist in all  
35 facets of the program should coverage of GLP-1 medications  
36 be appropriate;

37 (2) Evaluate the overall costs of coverage of GLP-1  
38 weight management medications in the context of potential  
39 savings from new drug pricing models;

40 (3) Continue to have conversations with providers and  
41 stakeholders in an effort to achieve optimal improved health  
42 outcomes and cost savings for the State of Alabama should  
43 coverage be appropriate; and

44 (4) Report its findings to the Legislature prior to  
45 the 2027 Legislative Session.



# HJR162 Enrolled

46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76

---

Speaker of the House of Representatives

---

President and Presiding Officer of the Senate

House of Representatives

I hereby certify that the within Act originated in  
and was passed by the House 26-Feb-26.

John Treadwell  
Clerk

Senate

---

**05-Mar-26**

---

Adopted